Role of miR-181a in the process of apoptosis of multiple malignant tumors: A literature review

Xialu Feng¹,², E, F, Chen Zhang¹,², F, Yan Yang³–⁴, F, Deren Hou³, D, F, Anding Zhu³, D, F

Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Abstract

It has been recognized that miR-181a expression is dysregulated and intimately associated with clinical prognosis in a variety of human cancers. However, the direct role of miR-181a in tumor progression has been elusive. Moreover, mounting evidence has demonstrated that cellular apoptosis, a physiological process of programmed cell death, is disrupted in various categories of human malignancies. Multiple apoptosis-related genes have been proven to act as the target genes of miR-181a. In this study, we hypothesize that miR-181a probably plays a potential role in modulating the procession and apoptosis of cancer cells. We performed a literature review and elucidated how miR-181a modulated cellular apoptosis, especially the malignant neoplasm cells. We also unraveled the potential role of miR-181a in the diagnosis, treatment and clinical prognosis of multiple human malignancies — miR-181a plays a pivotal role in the development, treatment and prognosis of patients suffering from malignant tumors. It also participates in the development of cancer partially by modulating cellular apoptosis.

Key words: miR-181a, apoptosis, Bcl-2 family, P53, PRKCD
Introduction

MicroRNAs (miRNAs) are defined as a class of highly-conserved, small non-coding RNA (22 nucleotides on average), which function to modulate gene expression at the posttranscriptional level by binding to the 3′-untranslated region (3′-UTR) of target genes. Previous investigations have demonstrated that the regulatory role of miRNAs is involved in multiple cellular processes, including cellular metabolism, proliferation, differentiation, development, and apoptosis. Aberrant expression of miRNAs contributes to the incidence and progression of malignant tumors, whereas the precise role of miRNAs in the development of malignant neoplasms remains elusive.1 As one of multiple conserved miRNAs among vertebrates, miR-181a has been confirmed to be differentially expressed in a variety of diseases, especially various cancers, and plays a critical role in the occurrence and development of malignant neoplasms.

Apoptosis is a physiological process of programmed cell death that is essential for normal tissue development and homeostasis, through which damaged, unattached, mutant, and aged cells are eliminated. Mounting evidence has demonstrated that miR-181a is capable of modulating cellular apoptosis by targeting several apoptosis-related genes, probably related to the underlying mechanism of the role of miR-181a involved in tumor progression. Aberrations in the signaling pathway can lead to degenerative and autoimmune disorders, and even cancer.5 This paper reviews the mechanism underlying the role of miR181-a involved in cellular apoptosis and investigates the correlation between miR-181a and varying human malignancies.

Apoptosis

Since apoptosis was first described in 1842 by Carl Vogt, accumulated studies have been performed to deepen the understanding of cellular apoptosis. As one of 2 major types of cell death, apoptosis is a highly-regulated process with specific and well-described morphological changes, and is critical for many physiological processes, including cell development, proliferation, differentiation, immune regulation, and eliminating defective and harmful cells. Dysfunction of apoptosis is central to multiple pathological states. For instance, enhanced apoptosis has been described in neurodegenerative diseases, e.g., acquired immunodeficiency syndrome (AIDS), transplant rejection and heart failure, whereas diminished apoptosis has been observed in autoimmune diseases, such as viral infections and even cancers.3–7

Currently, cancer is one of the major causes of a poor quality of life and human death. Common anticancer therapies, such as chemo- and radiotherapy, mainly induce the apoptosis of cancer cells by administration of cytotoxic agents. In 2014, Gong et al. demonstrated that Nexrutine® treatment could inhibit the growth of pancreatic cancer cells through induction of apoptosis.8 Targeting components of the apoptotic pathway has been regarded as a therapeutic approach for cancers, because aberrant apoptosis is central to the growth of malignant tumors and the resistance to anticancer therapies. Failures in normal apoptotic pathways contribute to carcinogenesis by creating a permissive environment for genetic instability and accumulation of gene mutations. In turn, tumor cells employ a variety of molecular mechanisms to suppress apoptosis, thus establishing a tumor/cancer-promoting loop.9

With deepening the understanding of the relationship between apoptosis and cancer, researchers have recently found that aberrant expression of miRNAs in tumor cells results in the dysfunction of cellular apoptosis. For instance, miR-106a overexpression significantly aggravated cellular apoptosis induced by cisplatin in ovarian cancer A2780 cells through downregulating the expression of antiapoptotic protein Mcl-1.10 Additionally, Ribeiro et al. summarized the function of human miRNAs in carcinogenesis and target genes.11 The let-7 family acts as a tumor suppressor by targeting c-Myc. It has been proven that the miR-15–16 cluster is an oncogene by interacting with Bcl-2. Interestingly, miR-125b plays a dual role, serving as an oncogene by regulating p53 and Bak-1 expression, whereas acting as a tumor suppressor during interaction with Bcl-2, Mcl-1, Bcl-w, etc. All these miRNA targets, including Bcl-2, Bcl-w, Bak-1, and Mcl-1, are capable of encoding the proteins associated with cellular apoptosis. Consequently, apoptosis dysfunction is implicated in the progression of malignant tumors. Especially in cancer cells, miRNAs are potentially capable of regulating the process of cellular apoptosis.

miR-181a and cancer

As a member of the miR-181 family, miRNA-181a has been intensively studied; miRNA-181a is located on the chromosome 1 (37.p5) and miR-181a2 is situated on the chromosome 9 (37.p5). Similar to other miRNAs, miR-181a plays a pivotal role in many cellular processes, such as cell fate determination and cellular invasion.12 It has been discovered to be abnormally expressed in solid malignant tumors and hematological malignancies. A significant downregulation of miR-181a level has been detected in squamous lung cell carcinoma, oral squamous cell carcinoma, salivary adenoid cystic carcinoma, acute myeloid leukemia, and non-small cell lung cancer, whereas evident overexpression of miR-181a level has been found in MCF-7 breast cancers, multiple myeloma, pancreatic and gastric cancer, and hepatocellular carcinoma.13–22 All these investigations have demonstrated that aberrant expression of miR-181a contributes to the development and metastasis of malignant tumors. In patients diagnosed with
colorectal cancer, miR-181a overexpression promotes CRC cell growth, invasion and liver metastasis by targeting the 3'-UTR of tumor suppressor gene WIF1. Additionally, upregulated expression of miRNA-181a can induce carcinogenesis by targeting EZF5 in hepatocellular carcinoma evolved from chronic hepatitis B.

Additionally, it has been revealed that high expression of miR-181a is associated with short recurrence time and poor outcome in patients with epithelial ovarian cancer. In a meta-analysis investigation, Lin et al. suggested that low expression of miR-181a/b is significantly associated with poor survival in patients with hematological malignancies.

Decades of research have indicated that miR-181a plays a critical role in tumorigenesis and cancer progression, whereas the mechanism underlying this function remains to be unraveled. Some scholars have indicated that, as a regulator of tumor phenotype, miR-181a is involved in tumorigenesis and downstream malignant processes through the ability to modulate the expression of critical genes and signaling networks which are mainly involved with regulating cell apoptosis. Hence, the influence on apoptosis is believed to be a vital mechanism for miR-181a to participate in tumor progression and development. In this review, the mechanisms underlying the role of miR-181a in cancer cellular apoptosis were retrospectively analyzed, and the correlation between miR-181a and the diagnosis, treatment and prognosis of malignant tumors was also briefly discussed.

miR-181a modulates apoptosis by targeting apoptosis-related genes

To mediate cellular apoptosis, 2 signaling pathways have been accepted: extrinsic and intrinsic. The extrinsic pathway of apoptosis is mediated by ligands activating death receptors, such as APO2L/TRAIL, FasL(Fas/ /APO1/CD95), TNF(TNFRI), etc. The intrinsic pathway of apoptosis is initiated in the mitochondria, and tightly regulated by the balance between pro-apoptotic (e.g., Bcl-1, Bax, Bim, and PS3) and anti-apoptotic genes (e.g., Bcl-1 and Mcl-1). Caspases, such as cysteine aspartic acid specific protease, serve as the central regulatory proteins in both extrinsic and intrinsic signaling pathways. Abrupt expression of regulatory genes results in deregulation of these pathways and subsequently leads to the incidence of multiple diseases. Recent research has verified that miR-181a could modulate cell apoptosis by targeting the apoptosis-related genes, including Bcl-2 family, PS3, ATM, PRKCD, PBX3, and RALA (Table 1).

### Bcl-2 gene family

The Bcl-2 gene family plays a pivotal role in the regulation of apoptosis via the mitochondrial pathway. The proteins of the Bcl-2 family are encoded, and consist of approx. 20 pro- and anti-apoptotic proteins falling into 3 groups. Anti-apoptotic multidomain members, such as Bcl-2, Mcl-1 and Bcl-w, contain BH1-4 domains, whereas pro-apoptotic multidomain proteins, including the Bax subfamily, contain BH1-3 domains. The BH3-only group, such as Bim, is proven to be pro-apoptotic. These proteins contribute to cellular apoptosis by regulating mitochondrial permeability, fission and fusion. Recent investigations have demonstrated that these proteins play a role in cellular homeostasis with respect to metabolism, calcium signaling, endoplasmic reticulum function, and autophagy.

### Table 1. Target genes and effect of miR-181a upon cellular apoptosis

<table>
<thead>
<tr>
<th>Target</th>
<th>Relationship</th>
<th>Tissues</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bcl-2</td>
<td>negative</td>
<td>breast cancer cell&lt;sup&gt;20&lt;/sup&gt;</td>
<td>enhance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>malignant glioma cell&lt;sup&gt;12&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CLL cell&lt;sup&gt;14&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AML cell&lt;sup&gt;15&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>prostate cancer cell&lt;sup&gt;17&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Mcl-1</td>
<td>negative</td>
<td>CLL cell&lt;sup&gt;40&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Bax</td>
<td>positive</td>
<td>NSCLC cell&lt;sup&gt;41&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Bim</td>
<td>negative</td>
<td>lymphoma cell&lt;sup&gt;42&lt;/sup&gt;</td>
<td>inhibit</td>
</tr>
<tr>
<td>PS3</td>
<td>positive</td>
<td>myeloma cell&lt;sup&gt;16&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>ATM</td>
<td>negative</td>
<td>gastric cancer cell&lt;sup&gt;44&lt;/sup&gt;</td>
<td>inhibit</td>
</tr>
<tr>
<td>PRKCD</td>
<td>negative</td>
<td>squamous cervical carcinoma cell&lt;sup&gt;46&lt;/sup&gt;</td>
<td>inhibit</td>
</tr>
<tr>
<td>PBX3</td>
<td>negative</td>
<td>acute myelogenous leukemia&lt;sup&gt;51&lt;/sup&gt;</td>
<td>enhance</td>
</tr>
<tr>
<td>RALa</td>
<td>negative</td>
<td>chonic myelogenous leukemia&lt;sup&gt;50&lt;/sup&gt;</td>
<td>enhance</td>
</tr>
</tbody>
</table>

### B-cell lymphoma 2

B-cell lymphoma 2 (Bcl-2), encoded by the Bcl2 gene in humans, is the founding member of the Bcl-2 family. It has been recognized that miR-181a can suppress Bcl-2 expression by targeting the 3'-UTR of the Bcl-2 gene. In spite of the negative relationship, western blotting has shown that the upregulation of Bcl-2 in MG63 cells is associated with the overexpression of miR-181a. In conclusion, miR-181a contributes to inducing and suppressing apoptosis via interaction with the Bcl-2 gene.

Chen et al. suggested that miR181a sensitizes human malignant glioma cells to radiation by targeting Bcl-2. MTT assay detected that cell growth rate was significantly reduced in miR-181a overexpressed cells after 18.8 Gy irradiation. Furthermore, they proved that the upregulation of miR-181a (exogenous miR-181a expression) resulted in a decrease in the expression of Bcl-2 protein. Khanna et al. proposed that overexpression of miR-34a, miR-30e and miR-181a could...
increase the rate of apoptosis, accompanied by a decline in Bcl-2 expression in miRNA-transfected mouse models. Li et al. constructed a luciferase reporter vector and identified a target site of miR-181a in the BCL-2 3’ UTR. K562 cells transfected with an miR-181a inhibitor had significantly higher survival compared to normal K562 cells, and K562/A02 cells transfected with a miR-181a mimic had a significantly lower survival than non-transfected K562/A02 cells, implying that miR181a can decrease the survival rate of the CLL cells treated by daunorubicin via targeting Bcl-2, regardless of whether the CLL cells are sensitive or resistant to daunorubicin. Bcl-2 was confirmed as a direct miR-181a target by immunoblot analysis and reporter gene assays. Bai et al. found that the Bcl-2 3’ UTR contains a highly-conserved 8mer site complementary to the seed region of the miR-181a. Moreover, they demonstrated that miR-181a can intensify caspase-dependent cell death through Bcl-2 in AML cells. Ouyang et al. established a mouse model and found that, compared to control cells, elevated expression of miR-181a reduced survival by 31%, whereas knockdown of endogenous miR-181a levels increased survival by 27%. Moreover, the downregulated levels of miR-181a are associated with reduced cell death and oxidative stress, and preserved mitochondrial function in astrocytes via upregulating Bcl-2 protein level. Zhai et al. observed that the expression levels significantly decreased, whereas miR-181a inhibition increased Bim levels by 6.5-fold.

Bim

Bim, as a member of the BH3-only family and Bcl-a protein family, contains only 1 single BH-domain. Bim plays a key role in promoting apoptosis. Lwin et al. demonstrated that adhesion of mantle cell lymphoma and other non-Hodgkin lymphoma cells to follicular dendritic cells reduced cell apoptosis and was associated with downregulated levels of Bim. Moreover, cell adhesion is capable of upregulating the expression of miR-181a; miR-181a overexpression decreased, whereas miR-181a inhibition increased Bim levels by directly targeting Bim. These results imply that miR-181a acts as a negative effector of the Bim-apoptosis signaling pathway.

Tumor protein p53

Tumor protein p53 (p53) is a transcription factor that activates or represses the expression of multiple genes. Numerous studies have established that p53 promotes apoptosis by transcriptionally activating or repressing the expression of a panel of pro- and anti-apoptotic proteins. Additionally, activation of p53-dependent apoptosis leads to mitochondrial apoptotic changes via both intrinsic and extrinsic pathways, triggering cell death notably by the release of cytochrome c and activation of caspase cascade. Pichierri et al. demonstrated that the miR-181a targets p300-CBP-associated factor and through p53 indirectly controls p53 activity in myeloma, and functions as a positive regulator of p53. Furthermore, Zhu et al. revealed that chronic lymphocytic leukemia cells transfected with miR-181a from p53 wild-type patients led to a significant increase in apoptosis, compared to miRNA controls. However, enforced expression of miR-181a exerted no effect on B-CLL cells from p53-attenuated patients, implying that miR-181a can enhance cellular apoptosis by targeting p53.

Myeloid cell leukemia-1

Myeloid cell leukemia-1 (Mcl-1) is the second member of the Bcl-2 family, which directly interacts with the BH3 alpha-helical domain of pro-apoptotic proteins, such as Bax, Bak, Bad, and Bim, and inhibits their functions. Ouyang et al. and Zhu et al. revealed that Bcl-1 is not only a direct target of miR-181a, but also miR-181a could enhance the cell apoptosis via negative interaction with Mcl-1.

Bax

As an apoptosis regulator, Bax, also known as Bcl-2-like protein 4, is a human protein encoded by the Bax gene. Bax is a member of the Bcl-2 gene family and promotes apoptosis by binding to and antagonizing the Bcl-2 protein. Galluzzi et al. suggested that miR-181a is capable of sensitizing NSCLC A549 cells to the lethal action of CDDP, carboplatin and oxaliplatin by stimulating Bax oligomerization, and the activation of pro-apoptotic caspases. Khanna et al. observed that the miR-34a, miR-30e and miR-181a not only modulate Bcl-2 expression, but down-regulate the expression of pro-apoptosis genes, such as Bax, and cleavage of caspases, and then gain neuronal survival in the brain of calorie-restricted mice. In brief, the positive relationship between miR-181a and Bax validates that miR-181a plays a pro-apoptotic role in both human and mouse cells.

Ataxia telangiectasia mutated

Ataxia telangiectasia mutated (ATM) is a serine/threonineprotein kinase that is recruited and activated by DNA double-strand breaks. ATM phosphorylates several
key proteins that initiate activation of the DNA damage checkpoint, leading to cell cycle arrest, DNA repair or apoptosis. Several of these targets, including p53, CHK2 and H2AX, are tumor suppressors. Zhang et al. demonstrated that ATM is a direct target of miR-181a, miR-181a mimics transfection downregulating the expression of ATM at both mRNA and protein levels. Additionally, compared to negative control and blank groups, transfection of miR-181a inhibitor is capable of inhibiting proliferation, invasion and migration, while promoting the apoptosis of SGC7901 cells. This data collectively indicates that overexpression of miR-181a promotes the proliferation, while suppressing the apoptosis of gastric cancer cells through directly targeting ATM.

**Protein kinase C delta type**

Protein kinase C delta type (PKC-δ), an enzyme encoded by the PRKCD gene, acts as a substrate for caspase-3. A series of studies have shown that PRKCD activity is required for apoptosis induced by DNA damaging agents, such as cisplatin, etoposide, cytosine arabinoside, mitomycin C, and doxorubicin. The regulating effect of PRKCD upon cellular apoptosis is highly complex. PKC-δ participates in oxLDL-induced endoplasmic reticulum stress-dependent apoptotic signaling through the IRE1α/JNK pathway. Moreover, PKC-δ plays a crucial role in the propagation of TNFα-induced endoplasmic reticulum stress-mediated JNK activation and CHOP/GADD53 induction. Recent research has revealed that the expression of PRKCD is modulated by miR-181a. Bergman et al. have demonstrated that the PRKCD gene is a direct target of miR-181a in a rat model of multiple sclerosis. Ke et al. and Chen et al. found that miR-181a could inhibit the irradiation- and cisplatin-induced apoptosis of human squamous cervical carcinoma cells via downregulating the expression levels of PRKCD.

**PBX3**

PBX3, a HOXA cofactor gene, can encode pre-B-cell leukemia transcription factor 3, which is capable of regulating the transcription of downstream targets by forming stable heterocomplexes with HOX and MEIS proteins. In human leukemic cells carrying MLL rearrangements, ectopic expression of miR-495 significantly inhibits cell viability and increases cell apoptosis via directly targeting the PBX3 gene, implying that PBX3 could regulate cellular apoptosis, but the underling mechanism remains elusive. Li et al. demonstrated that miR-181a possesses the same function as miR-495. Upregulated expression of miR-181a significantly promotes cellular apoptosis, inhibits the viability and proliferation of leukemic cells, and delays leukemogenesis by downregulating the endogenous expression of PBX3 at both the RNA and protein levels.

The effect of miR-181a upon the growth and apoptosis of leukemic cells depends on the PBX3 signaling pathway.

**RalA**

RalA, as an important effector of Ras, is proven to be involved in tumorigenesis and cancer invasion, and over-activated in multiple human cancers, such as malignant peripheral nerve sheath tumor, non-small cell lung cancer and chronic myeloid leukemia. Male et al. demonstrated that the proliferation and invasiveness of A549 cells were reduced upon silencing RalA, whereas apoptosis and necrosis were enhanced in such conditions in non-small cell lung cancer cell lines. Zhu et al. investigated that siRNA RalA, used to reduce RalA protein level in K562 and KCL-22 cells, effectively inhibited cell viability by significantly increasing caspase 3 activity, and CML cells transfected with siRNA RalA acquired typical features of apoptosis, including nuclear pyknosis, fragmentation and apoptotic body at 48-h post-transfection. This evidence validated that downregulation of RalA can induce cell apoptosis. Fei et al. demonstrated that miR-181a could downregulate the expression of RalA. The dual-luciferase reporter and western blot assays confirmed that RalA contains a miR-181a binding site at its 3’-UTR and is directly regulated by miR-181a. Additionally, immunoblot and RT-PCR revealed that overexpression of miR-181a significantly downregulates the expression level of RalA mRNA, subsequently suppresses cell growth, and eventually induces G2-phase arrest and apoptosis in leukemia K562 cells.

**Programmed cell death 4**

The programmed cell death 4 (PDCD4) gene functions to encode a protein localized within the nucleus in proliferating cells. The product of PDCD4 is thought to play a role in apoptosis, but the specific role has not been determined. Previous investigations have indicated that PDCD4 protein was downregulated in HCC tissues, and Huh7 cells transfected with PDCD4 resulted in upregulated expression of cytosolic cytochrome complex (cyt c) and mitochondrial Bax accompanied by downregulated levels of mitochondrial cyt c and cytosolic Bax. Furthermore, a slight reduction of procaspase-8, and a significant reduction of procaspase-9 and procaspase-3 were observed after PDCD4 transfection. These results indicate that PDCD4 might induce apoptosis via mitochondria events and caspase cascade. Additionally, the PDCD4 gene is originally identified as a tumor-related gene in humans and acts as a tumor suppressor in mouse epidermal carcinoma cells, prompting that the suppressing effect of PDCD4 upon malignant tumors could be regulated by miR-21 and miR-106a. Daisuke et al. demonstrated that PDCD4 is a target gene of miR-181a, and the increased miR-181a levels were
significantly associated with shortened disease-free survival and overall survival of breast cancer patients, whereas low expression of PDCD4 was significantly correlated with poorer disease-free survival.\textsuperscript{39} However, no statistical significance was observed between PDCD4 gene expression and accumulation of miR-181a. The regulating effect upon cellular apoptosis is complex, and deeper understanding of the relationship between miR-181a and PDCD4 and other apoptosis-related genes is urgently required.

**Conclusions**

The mechanism underlying the role of miRNAs involved in the pathogenesis of malignant neoplasm remains an emphasis. Malignant neoplasm represents a broad group of diseases involving unregulated cell growth, implying that abnormal cellular apoptosis plays a pivotal role in the development of malignancies.

In this paper, we conducted a literature review to elucidate how miR-181a modulates cellular apoptosis. Specifically, miR-181a modulates apoptosis by targeting the apoptosis-related genes. The enhancing/inhibiting apoptosis balance is probably explained by the direct interaction between miR-181a and alternative apoptosis-related genes. It has been recognized that miR-181a is capable of enhancing apoptosis of cells, particularly in malignant tumor cells, by targeting p53, Bax, Bcl-2, PBX3, and RalA, while suppressing apoptosis by interacting with PRKCD, ATM, Bim, and Bcl-2.

Depending on the different functions involved in the apoptotic process and aberrant expression in cancer cells, miR-181a could dually act as oncogene and tumor suppressors, as illustrated in Table 2. Despite the fact that miR-181a is involved in cancer development, overexpression of miR-181a sensitizes cancer cells to drugs and radiation via targeting apoptosis-related genes.\textsuperscript{29,31,36,42} Additionally, miR-181a contributes to the bufalin-induced apoptosis and cisplatin-induced apoptosis of cancer cells.\textsuperscript{35,38} Based on the role of miR-181a in chemotherapy or radiotherapy, miR-181a might be a potential target for the treatment of varying cancers. The predictive role miR-181a plays in epithelial ovarian cancer and hematological malignancies verifies that miR-181a levels could be used as a potential prognostic biomarker predicting the clinical prognosis of cancer patients.

Taken together, miR-181a plays a pivotal role in the development, treatment and prognosis of patients suffering from malignant tumors. It participates in the development of cancer partially by modulating cellular apoptosis. Nevertheless, the exact role of miR-181a in different malignancies remains to be elucidated. If miR-181a could serve as a clinical parameter, prognostic biomarkers in different types of cancer should be subsequently validated by clinical investigations.

**References**

15. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S. Deregulated expression of miR-21, miR-141 and miR-181a in non small cell lung cancer is relat-

### Table 2. Relationship between miR-181a and development and apoptosis of malignant tumors

<table>
<thead>
<tr>
<th>Expression of miR-181a</th>
<th>Tissues</th>
<th>Regulation on apoptosis process</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced</td>
<td>malignant glioma cell\textsuperscript{12}</td>
<td>enhance oncogene</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLL cell\textsuperscript{14,40}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AML cell\textsuperscript{10,21,31}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CML cell\textsuperscript{15}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>prostate cancer cell\textsuperscript{17,50}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NSCLC cell\textsuperscript{15,41}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>osteosarcoma cell\textsuperscript{17}</td>
<td>inhibit oncogene</td>
<td></td>
</tr>
<tr>
<td></td>
<td>lymphoma cell\textsuperscript{12}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>gastric cancer cell\textsuperscript{27,44}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>squamous cervical carcinoma cell\textsuperscript{18,49}</td>
<td>enhance tumor suppressor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>breast cancer cell\textsuperscript{8,30}</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>myeloma cell\textsuperscript{19}</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{...}
ed to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010;64:399–408.


